Niridazole suppression of experimental allergic encephalomyelitis in Lewis rats.
Administration of niridazole to Lewis rats beginning 2 days before sensitization with guinea pig spinal cord in combination with immunologic adjuvants exerted a dose related suppressive influence on development of experimental allergic encephalomyelitis (EAE). A daily dose of 75 mg/kg completely prevented clinical neurologic signs as well as markedly suppressed occurrence of immunohistopathologic manifestations of this autoimmune disease. A higher daily dose level of niridazole, i.e., 100 mg/k, also inhibited EAE but was associated with neurotoxic manifestations.
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology*; D005260:Female; D005620:Freund's Adjuvant / Q000494:pharmacology; D006168:Guinea Pigs; D007166:Immunosuppressive Agents; D008297:Male; D009461:Neurologic Manifestations / Q000209:etiology; D009560:Niridazole; D010567:Pertussis Vaccine / Q000494:pharmacology; D051381:Rats; D011917:Rats, Inbred Lew; D013116:Spinal Cord / Q000276:immunology
D007166:Immunosuppressive Agents; D010567:Pertussis Vaccine; D005620:Freund's Adjuvant; D009560:Niridazole